Oxford’s AstraZeneca Vaccine Is 70% Effective On COVID-19

By Erica Nsunjo / Published November 24, 2020 | 12:19 pm



vaccine-vaccines

The AstraZeneca is a vaccine developed by the University of Oxford and AstraZeneca Plc prevented a majority of people from getting the disease, an average of 70 percent of participants in a study from falling ill, an early analysis of the data shows.

The analysis also shows that the effectiveness rose to 90 percent for one of two regimens, using half a dose followed by a full one later, close to the high bar set by Pfizer Inc. and Moderna Inc.

The head of AstraZeneca in France, Olivier Nataf said they will be producing three billion doses worldwide in 2021. He added that production is ramping up, there are already 50 million doses of active substances available and capacity is being increased almost weekly.

The producers of the AstraZeneca vaccine said they are committed to these three billion doses at a cost price for 2021. “We must not forget that this is a race against the virus rather than a race for the vaccine between competitors,” Nataf added

Natafa also added that production is underway and that the first agreements with various governments and non-governmental organizations have been announced.

Additionally, the price of the vaccine is around 2.50 euros ($3) per dose. “This is the main subject of our agreement with Oxford, in order to be able to provide this vaccine to the widest possible population, under the most equitable conditions of access possible,” Nataf said

“Our goal was to make sure we can have a vaccine that is accessible everywhere,” Andrew Pollard, who is leading the Astra-Oxford trials, said Monday at a press briefing. “I think we have actually managed to do that.”

Meanwhile, earlier reports indicated that Africa might need 1,200,000,000,000 shillings to access the coming COVID-19 vaccine. The African Union has a commitment of 500,000,000,000 shillings promised by the World Bank and other donors.

The African Union informed African Nations during a meeting following an announcement by global pharmaceutical companies Pfizer and BioNTec that their vaccine candidate was showing 90 percent efficacy

The COVID-19 vaccine, being developed jointly with German firm BioNTech, is one of more than 40 candidate vaccines, but no other has yet made similar claims about its effectiveness.

The vaccine US pharmaceutical giant Pfizer said tests involving more than 40,000 people had provided results that were a “critical milestone” in the search for a vaccine.

According to Moussa Faki Mahamat, Chairperson of the African Union Commission, Africa needs to vaccinate around 60 percent of the population to arrest further transmission and death from COVID-19.





About Erica Nsunjo

Nsunjo Erica is a Practicing Journalist / Activist / Patriot / Practicing Politician / Practicing Entrepreneur / aspiring Lawyer, and a proud Ugandan. Because the journey is not static, I am molding it accordingly.

View other posts by Erica Nsunjo


More Articles From This Author






Trending Stories










Other Related Articles










SOKO DIRECTORY & FINANCIAL GUIDE



ARCHIVES

2021
  • January 2021 (154)
  • 2020
  • January 2020 (272)
  • February 2020 (310)
  • March 2020 (390)
  • April 2020 (321)
  • May 2020 (335)
  • June 2020 (327)
  • July 2020 (334)
  • August 2020 (276)
  • September 2020 (214)
  • October 2020 (233)
  • November 2020 (242)
  • December 2020 (187)
  • 2019
  • January 2019 (253)
  • February 2019 (216)
  • March 2019 (285)
  • April 2019 (254)
  • May 2019 (272)
  • June 2019 (251)
  • July 2019 (338)
  • August 2019 (293)
  • September 2019 (306)
  • October 2019 (313)
  • November 2019 (362)
  • December 2019 (319)
  • 2018
  • January 2018 (291)
  • February 2018 (213)
  • March 2018 (278)
  • April 2018 (225)
  • May 2018 (237)
  • June 2018 (178)
  • July 2018 (256)
  • August 2018 (249)
  • September 2018 (256)
  • October 2018 (287)
  • November 2018 (284)
  • December 2018 (185)
  • 2017
  • January 2017 (183)
  • February 2017 (194)
  • March 2017 (207)
  • April 2017 (104)
  • May 2017 (169)
  • June 2017 (205)
  • July 2017 (190)
  • August 2017 (195)
  • September 2017 (186)
  • October 2017 (235)
  • November 2017 (253)
  • December 2017 (266)
  • 2016
  • January 2016 (165)
  • February 2016 (165)
  • March 2016 (190)
  • April 2016 (143)
  • May 2016 (245)
  • June 2016 (182)
  • July 2016 (271)
  • August 2016 (248)
  • September 2016 (234)
  • October 2016 (191)
  • November 2016 (243)
  • December 2016 (153)
  • 2015
  • January 2015 (1)
  • February 2015 (4)
  • March 2015 (166)
  • April 2015 (108)
  • May 2015 (116)
  • June 2015 (120)
  • July 2015 (148)
  • August 2015 (157)
  • September 2015 (188)
  • October 2015 (169)
  • November 2015 (173)
  • December 2015 (207)
  • 2014
  • March 2014 (2)
  • 2013
  • March 2013 (10)
  • June 2013 (1)
  • 2012
  • March 2012 (7)
  • April 2012 (15)
  • May 2012 (1)
  • July 2012 (1)
  • August 2012 (4)
  • October 2012 (2)
  • November 2012 (2)
  • December 2012 (1)
  • 2011
    2010
    2009
    2008
    2007
    2006
    2005
    2004
    2003
    2002
    2001
    2000
    1999
    1998
    1997
    1996
    1995
    1994
    1993
    1992
    1991
    1990
    1989
    1988
    1987
    1986
    1985
    1984
    1983
    1982
    1981
    1980
    1979
    1978
    1977
    1976
    1975
    1974
    1973
    1972
    1971
    1970
    1969
    1968
    1967
    1966
    1965
    1964
    1963
    1962
    1961
    1960
    1959
    1958
    1957
    1956
    1955
    1954
    1953
    1952
    1951
    1950